AN2 Therapeutics
ANTX
45 hedge funds and large institutions have $41.7M invested in AN2 Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 14 closing their positions.
2.1% more ownership
Funds ownership: 62.99% → 65.09% (+2.1%)
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
17% less funds holding
Funds holding: 54 → 45 (-9)
31% less capital invested
Capital invested by funds: $60.9M → $41.7M (-$19.1M)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$5.04M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$1.67M |
| 3 |
Millennium Management
New York
|
+$1.02M |
| 4 |
Goldman Sachs
New York
|
+$466K |
| 5 |
Two Sigma Advisers
New York
|
+$321K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$4.03M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$3.74M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$408K |
| 4 |
UBS AM
Chicago,
Illinois
|
-$248K |
| 5 |
Jane Street
New York
|
-$192K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
XT
51
XTX Topco
George Town,
Cayman Islands
| – | -$126K | -38,666 | Closed |
|
52
Barclays
London,
United Kingdom
| – | -$92K | -28,318 | Closed |
|
|
HF
53
HRT Financial
New York
| – | -$79K | -24,366 | Closed |
|
|
CPIG
54
Chicago Partners Investment Group
Chicago,
Illinois
| – | -$52.1K | -22,001 | Closed |
|
55
Swiss National Bank
Zurich,
Switzerland
| – | -$66.9K | -20,575 | Closed |
|
|
AI
56
Atom Investors
Austin,
Texas
| – | -$38.7K | -11,905 | Closed |
|
|
SSG
57
Summit Securities Group
New York
| – | -$33K | -10,000 | Closed |
|
58
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
| – | -$30.1K | -9,251 | Closed |
|
59
Wells Fargo
San Francisco,
California
| – | -$416 | -128 | Closed |
|
ANTX Hedge Fund Activity: Q2 2024 in Review
45 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in AN2 Therapeutics (ANTX) for Q2 2024, worth a combined $41.7M — down 31% from $60.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of ANTX and 6 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 14 added.
The largest buyer was Octagon Capital Advisors, adding an estimated $5.04M. The largest seller was BVF Inc, exiting entirely with an estimated $4.03M sold.
- 45 institutional investors held AN2 Therapeutics (ANTX) as of Q2 2024, down from 54 in Q1 2024.
- Funds reported $41.7M of AN2 Therapeutics stock for Q2 2024, down 31% quarter-over-quarter.
- 6 funds opened new AN2 Therapeutics positions in Q2 2024 and 14 closed out, a net change of -8 holders.
- The largest AN2 Therapeutics buyer in Q2 2024 was Octagon Capital Advisors, an estimated $5.04M added.
- The largest AN2 Therapeutics seller in Q2 2024 was BVF Inc, an estimated $4.03M sold.
Based on aggregated 13F filings for Q2 2024.